The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s exhibiting significant efficacy in clinical trials for managing obesity. Unlike some current weight loss treatments, retatrutide appears to provide a greater substantial dec